Publication date: Dec 01, 2019
We sought to determine if a proteomic profile approach developed to detect Alzheimer’s disease would distinguish patients with Lewy body disease from normal controls, and if it would distinguish dementia with Lewy bodies (DLB) from Parkinson’s disease (PD).
Stored plasma samples were obtained from 145 patients (DLB n = 57, PD without dementia n = 32, normal controls n = 56) enrolled from patients seen in the Behavioral Neurology or Movement Disorders clinics at the Mayo Clinic, Florida. Proteomic assays were conducted and analyzed as per our previously published protocols.
In the first step, the proteomic profile distinguished the DLB-PD group from controls with a diagnostic accuracy of 0.97, sensitivity of 0.91, and specificity of 0.86. In the second step, the proteomic profile distinguished the DLB from PD groups with a diagnostic accuracy of 0.92, sensitivity of 0.94, and specificity of 0.88.
These data provide evidence of the potential utility of a multitiered blood-based proteomic screening method for detecting DLB and distinguishing DLB from PD.
Open Access PDF
O’Bryant, S.E., Ferman, T.J., Zhang, F., Hall, J., Pedraza, O., Wszolek, Z.K., Como, T., Julovich, D., Mattevada, S., Johnson, L.A., Edwards, M., Hall, J., and Graff-Radford, N.R. A proteomic signature for dementia with Lewy bodies. 23140. 2019 Alzheimers Dement (Amst) (11):
|disease||MESH||Lewy body disease|
- Potential two-step proteomic signature for Parkinson’s disease: Pilot analysis in the Harvard Biomarkers Study.
- Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson’s Disease.